查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1617750

人類抗菌藥物敏感性測試市場：按類型、產品、方法、應用和最終用戶分類 - 全球預測 2025-2030

Human Antimicrobial Susceptibility Testing Market by Type, Product, Method, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年，人類抗菌藥物敏感性測試市場價值為37.1億美元，預計到2024年將達到39.2億美元，複合年成長率為5.88%，到2030年將達到55.4億美元。

人類抗菌藥物敏感性測試市場涉及評估病原體以確定其對特定抗菌藥物的敏感性，以確保感染疾病的準確治療和管理。該測試旨在對抗日益成長的抗菌素抗藥性（AMR）威脅，促進臨床實踐中的明智決策，指導精準醫療，並支持新抗生素開發的藥物研究。典型應用包括醫院、診斷中心和實驗室，最終用戶包括醫療保健提供者和製藥公司。市場成長的主要驅動力是感染疾病的日益普及、對快速診斷技術的需求以及對抗菌素抗藥性的認知不斷提高。自動化系統和分子診斷工具等技術進步是市場擴張的主要機會。然而，先進測試技術的高成本、低收入地區的准入有限以及開發標準化測試通訊協定的複雜性等因素阻礙了市場開拓。為了利用成長機會，公司應投資開發具有成本效益的快速診斷技術，並擴大夥伴關係，以提高在開發中國家的市場滲透率。這是將人工智慧和機器學習整合到抗菌藥物敏感性測試中以提高預測準確性和效率的寶貴機會。此外，個人化醫療的不斷成長趨勢為開發客製化抗菌解決方案提供了途徑。挑戰包括監管障礙以及需要持續創新以解決不斷變化的細菌抗藥性。企業也需要預測並適應監管環境的變化，以避免潛在的市場進入障礙。專注於提高現場測試和測試準確性的創新為業務成長提供了巨大的潛力。市場是動態的，其特點是技術快速進步和嚴格的法規環境，這使得持續的研發和策略聯盟對於公司保持競爭力和長期成功至關重要。

主要市場統計
基準年[2023] 37.1億美元
預計年份 [2024] 39.2億美元
預測年份 [2030] 55.4億美元
複合年成長率（%） 5.88%

市場動態：快速發展的人類抗菌藥物敏感性測試市場的關鍵市場洞察

供需的動態交互作用正在改變人類抗菌藥物敏感性測試市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 由於病原體增加導致感染疾病率增加
    • 政府措施提高抗菌素抗藥性意識並遏制抗菌素過度使用
    • 生物製藥公司抗菌藥物敏感性測試的使用迅速增加
  • 市場限制因素
    • 自動化抗菌藥物敏感性測試高成本
  • 市場機會
    • 人類 AST 方法快速發展的技術進步
    • 增加市場資金、研究津貼以及公共和私人投資
  • 市場挑戰
    • 開發中國家複雜的法律規範與測試問題

波特五力：引領人類抗菌藥物敏感性測試市場的策略工具

波特五力是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解人類抗菌藥物敏感性測試市場的外部影響

外部宏觀環境因素在塑造人類抗菌藥物敏感性測試市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解人類抗菌藥物敏感性測試市場的競爭格局

對人類抗菌藥物敏感性測試市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的見解，以應對日益激烈的競爭。

FPNV 定位矩陣人類抗菌藥物敏感性測試市場供應商的績效評估

FPNV定位矩陣是評估人類抗菌藥物敏感性測試市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃人類抗菌藥物敏感性測試市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對人類抗菌藥物敏感性測試市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 由於病原體數量增加，感染疾病傳播加劇
      • 政府加強提高人們對抗菌藥物抗藥性的認知並遏制抗菌藥物濫用
      • 生物製藥公司對抗菌藥物敏感性測試的使用正在迅速增加
    • 抑制因素
      • 自動化抗菌藥物敏感性測試高成本
    • 機會
      • 開發快速人類 AST 檢測方法的技術進步
      • 增加市場資金、研究津貼以及公共和私人投資
    • 任務
      • 新興國家複雜的法規結構與測試挑戰
  • 市場區隔分析
    • 類型：增加研發投入，開發下一代藥敏試驗
    • 最終使用者：醫院和診斷中心對指導病患特定治療策略的需求不斷增加
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章人體抗菌藥物敏感性測試市場：按類型

  • 抗生素敏感性測試
  • 抗真菌藥物敏感性試驗
  • 抗寄生蟲藥敏試驗

第7章人體抗菌藥物敏感性測試市場：依產品

  • 自動化實驗室設備
  • 消耗品
  • 文化和生長媒體
  • 手動抗菌藥物敏感性測試產品

第8章人體抗菌藥物敏感性測試市場：依方法分類

  • 瓊脂稀釋液
  • 自動藥敏試驗設備
  • 圓盤擴散
  • 電子測試方法
  • 基因型鑒定方法

第9章人體抗菌藥物敏感性測試市場：依應用分類

  • 臨床診斷
  • 藥物發現與開發
  • 流行病學

第10章人類抗菌藥物敏感性測試市場：依最終用戶分類

  • 合約調查機構
  • 醫院和診斷中心
  • 製藥/生物技術
  • 研究/學術機構

第11章美洲人體抗菌藥物敏感性測試市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太人類抗生素敏感性測試市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲人體抗菌藥物敏感性測試市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 對快速診斷技術進行策略性投資，以消除抗生素抗藥性淋病並利用 CARB-X 加強全球性行為感染傳染病控制
    • 微孔盤獲得資金用於對抗抗菌素抗藥性的創新
    • 希森美康快速抗菌藥物敏感性測試系統簡介
  • 戰略分析和建議

公司名單

  • Alifax Srl
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • BIOANALYSE TIBBI MALZ
  • BioMerieux SA
  • Biosafe Ltd.
  • Bruker Corporation
  • Creative Diagnostics
  • ELITech Group SAS
  • Erba Lachema sro
  • F. Hoffmann-La Roche AG
  • Genefluidics, Inc.
  • Himedia Laboratories Private Limited
  • INTEGRA Biosciences AG
  • Laboratorios Conda, SA
  • Launch Diagnostics Limited
  • Liofilchem Srl
  • Mast Group Ltd.
  • Merck KGaA
  • Pfizer Inc.
  • Thermo Fisher Scientific Inc.
  • Zhuhai DL Biotech Co., Ltd.
Product Code: MRR-4E27A4DF1227

The Human Antimicrobial Susceptibility Testing Market was valued at USD 3.71 billion in 2023, expected to reach USD 3.92 billion in 2024, and is projected to grow at a CAGR of 5.88%, to USD 5.54 billion by 2030.

The human antimicrobial susceptibility testing market involves the evaluation of pathogens to determine their susceptibility to specific antimicrobial agents, ensuring accurate treatment and management of infections. This testing is essential in combating the rising threat of antimicrobial resistance (AMR), facilitating informed decisions in clinical settings, guiding precision medicine, and aiding pharmaceutical research in novel antibiotic development. Key applications include hospitals, diagnostic centers, and research laboratories, while end-users range from healthcare providers to pharmaceutical firms. Market growth is significantly driven by the increasing prevalence of infectious diseases, the need for rapid diagnostic techniques, and a rising awareness of AMR. Technological advancements, such as automated systems and molecular diagnostic tools, present substantial opportunities for enhancement. However, market growth is hindered by factors like the high costs associated with advanced testing technologies, limited access in low-income regions, and the complexity of developing standardized testing protocols. To capitalize on growth opportunities, firms should invest in developing cost-effective and rapid diagnostic technologies, and expand partnerships to increase market penetration in developing nations. There's a valuable opportunity in integrating AI and machine learning into antimicrobial susceptibility testing to enhance predictive accuracy and efficiency. Moreover, the growing trend towards personalized medicine offers avenues for developing tailored antimicrobial solutions. Challenging factors include regulatory hurdles and the need for continual innovation to keep pace with evolving bacterial resistance. Firms should also anticipate and adapt to changes in the regulatory landscape to avoid potential market entry barriers. Innovations focusing on point-of-care testing and enhancing testing accuracy offer significant potential for business growth. As the market is dynamic, characterized by rapid technological advancements and stringent regulatory environments, continuous R&D and strategic partnerships will be crucial for businesses to maintain a competitive edge and drive long-term success.

KEY MARKET STATISTICS
Base Year [2023] USD 3.71 billion
Estimated Year [2024] USD 3.92 billion
Forecast Year [2030] USD 5.54 billion
CAGR (%) 5.88%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Human Antimicrobial Susceptibility Testing Market

The Human Antimicrobial Susceptibility Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of infectious diseases due to the rising pathogens
    • Rising government initiatives to create awareness of antimicrobial resistance and curb antimicrobial abuse
    • Surging use of antimicrobial susceptibility testing by biopharmaceutical companies
  • Market Restraints
    • High cost of automated antimicrobial susceptibility testing
  • Market Opportunities
    • Technological advancements towards the development of rapid human AST methods
    • Increasing funding, research grants, and public-private investments in the market
  • Market Challenges
    • Complex regulatory frameworks coupled with issues in testing in developing countries

Porter's Five Forces: A Strategic Tool for Navigating the Human Antimicrobial Susceptibility Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Human Antimicrobial Susceptibility Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Human Antimicrobial Susceptibility Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Human Antimicrobial Susceptibility Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Human Antimicrobial Susceptibility Testing Market

A detailed market share analysis in the Human Antimicrobial Susceptibility Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Human Antimicrobial Susceptibility Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Human Antimicrobial Susceptibility Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Human Antimicrobial Susceptibility Testing Market

A strategic analysis of the Human Antimicrobial Susceptibility Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Human Antimicrobial Susceptibility Testing Market, highlighting leading vendors and their innovative profiles. These include Alifax S.r.l., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., BIOANALYSE TIBBI MALZ, BioMerieux SA, Biosafe Ltd., Bruker Corporation, Creative Diagnostics, ELITech Group SAS, Erba Lachema s.r.o., F. Hoffmann-La Roche AG, Genefluidics, Inc., Himedia Laboratories Private Limited, INTEGRA Biosciences AG, Laboratorios Conda, S.A., Launch Diagnostics Limited, Liofilchem S.r.l., Mast Group Ltd., Merck KGaA, Pfizer Inc., Thermo Fisher Scientific Inc., and Zhuhai DL Biotech Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Human Antimicrobial Susceptibility Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Antibacterial Susceptibility Testing, Antifungal Susceptibility Testing, and Antiparasitic Susceptibility Testing.
  • Based on Product, market is studied across Automated Laboratory Instruments, Consumables, Culture & Growth Media, and Manual Antimicrobial Susceptibility Testing Products.
  • Based on Method, market is studied across Agar Dilution, Automated Susceptibility Testing Instruments, Disk Diffusion, Etest Method, and Genotyping Methods.
  • Based on Application, market is studied across Clinical Diagnostics, Drug Discovery & Development, and Epidemiology.
  • Based on End User, market is studied across Contract Research Organizations, Hospital & Diagnostic Centers, Pharmaceutical & Biotechnology, and Research & Academic Institutes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of infectious diseases due to the rising pathogens
      • 5.1.1.2. Rising government initiatives to create awareness of antimicrobial resistance and curb antimicrobial abuse
      • 5.1.1.3. Surging use of antimicrobial susceptibility testing by biopharmaceutical companies
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of automated antimicrobial susceptibility testing
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements towards the development of rapid human AST methods
      • 5.1.3.2. Increasing funding, research grants, and public-private investments in the market
    • 5.1.4. Challenges
      • 5.1.4.1. Complex regulatory frameworks coupled with issues in testing in developing countries
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Rising R&D investment to develop next generation susceptibility testing
    • 5.2.2. End User: Rising demand across hospital & diagnostic centers to guide patient-specific treatment strategies
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Human Antimicrobial Susceptibility Testing Market, by Type

  • 6.1. Introduction
  • 6.2. Antibacterial Susceptibility Testing
  • 6.3. Antifungal Susceptibility Testing
  • 6.4. Antiparasitic Susceptibility Testing

7. Human Antimicrobial Susceptibility Testing Market, by Product

  • 7.1. Introduction
  • 7.2. Automated Laboratory Instruments
  • 7.3. Consumables
  • 7.4. Culture & Growth Media
  • 7.5. Manual Antimicrobial Susceptibility Testing Products

8. Human Antimicrobial Susceptibility Testing Market, by Method

  • 8.1. Introduction
  • 8.2. Agar Dilution
  • 8.3. Automated Susceptibility Testing Instruments
  • 8.4. Disk Diffusion
  • 8.5. Etest Method
  • 8.6. Genotyping Methods

9. Human Antimicrobial Susceptibility Testing Market, by Application

  • 9.1. Introduction
  • 9.2. Clinical Diagnostics
  • 9.3. Drug Discovery & Development
  • 9.4. Epidemiology

10. Human Antimicrobial Susceptibility Testing Market, by End User

  • 10.1. Introduction
  • 10.2. Contract Research Organizations
  • 10.3. Hospital & Diagnostic Centers
  • 10.4. Pharmaceutical & Biotechnology
  • 10.5. Research & Academic Institutes

11. Americas Human Antimicrobial Susceptibility Testing Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Human Antimicrobial Susceptibility Testing Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Human Antimicrobial Susceptibility Testing Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Strategic Investment in Rapid Diagnostic Technologies by CARB-X to Combat Antibiotic-Resistant Gonorrhea and Enhance Global STI Management
    • 14.3.2. Microplate Secures Funding for Innovation in Combatting Antimicrobial Resistance
    • 14.3.3. Introducing Sysmex's Rapid Antimicrobial Susceptibility Testing System
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Alifax S.r.l.
  • 2. Becton, Dickinson and Company
  • 3. Bio-Rad Laboratories, Inc.
  • 4. BIOANALYSE TIBBI MALZ
  • 5. BioMerieux SA
  • 6. Biosafe Ltd.
  • 7. Bruker Corporation
  • 8. Creative Diagnostics
  • 9. ELITech Group SAS
  • 10. Erba Lachema s.r.o.
  • 11. F. Hoffmann-La Roche AG
  • 12. Genefluidics, Inc.
  • 13. Himedia Laboratories Private Limited
  • 14. INTEGRA Biosciences AG
  • 15. Laboratorios Conda, S.A.
  • 16. Launch Diagnostics Limited
  • 17. Liofilchem S.r.l.
  • 18. Mast Group Ltd.
  • 19. Merck KGaA
  • 20. Pfizer Inc.
  • 21. Thermo Fisher Scientific Inc.
  • 22. Zhuhai DL Biotech Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET DYNAMICS
  • TABLE 7. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIBACTERIAL SUSCEPTIBILITY TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIFUNGAL SUSCEPTIBILITY TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIPARASITIC SUSCEPTIBILITY TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED LABORATORY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CULTURE & GROWTH MEDIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AGAR DILUTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SUSCEPTIBILITY TESTING INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ETEST METHOD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GENOTYPING METHODS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY EPIDEMIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY HOSPITAL & DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 240. HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 241. HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, FPNV POSITIONING MATRIX, 2023